Use of cetuximab in combination with pulsed reduced dose-rate radiotherapy in a patient with recurrence of nasopharyngeal carcinoma in the neck

Experimental and Therapeutic Medicine

Volumn 3, Issue 5, 2012, Pages 869-872

  Li, Guang Hui ^a   Zhu, Bo ^a   Yang, Fan ^a   Ma, Chuan Kun ^a   Yang, Ding Qiang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cetuximab; Nasopharyngeal carcinoma; Pulsed reduced dose rate radiotherapy; Recurrence

Indexed keywords

CETUXIMAB; CISPLATIN; FLUOROURACIL; PACLITAXEL;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DISEASE SEVERITY; ECHOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NASOPHARYNGEAL CARCINOMA IN THE NECK; NASOPHARYNGEAL CARCINOMA OF THE NECK; NASOPHARYNX CARCINOMA; OUTCOME ASSESSMENT; PULSED REDUCED DOSE RATE RADIOTHERAPY; RADIATION DOSE DISTRIBUTION; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK; SQUAMOUS CELL CARCINOMA OF THE THORAX; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR VOLUME;

EID: 84863352668     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.506     Document Type: Article

References (18)

1. Shen C, Gao Y, Xu T, et al: Carcinoma of the nasopharynx in young patients: a single institution experience. Clin Oncol (R Coll Radiol) 21: 617-622, 2009.
2. Yi JL, Gao L, Huang XD, et al: Nasopharyngeal carcinoma treated by radical radiotherapy alone: ten-year experience of a single institution. Int J Radiat Oncol Biol Phys 65: 161-168, 2006.
3. Sher DJ, Haddad RI, Norris CM, et al: Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer. Cancer 116: 4761-4768, 2010.
4. Adkison JB, Tomé W, Seo S, et al: Reirradiation of large-volume recurrent glioma with pulsed reduced-dose-rate radiotherapy. Int J Radiat Oncol Biol Phys 79: 835-841, 2011.
5. Richards GM, Tomé WA, Robins HI, et al: Pulsed reduced dose-rate radiotherapy: a novel locoregional retreatment strategy for breast cancer recurrence in the previously irradiated chest wall, axilla, or supraclavicular region. Breast Cancer Res Treat 114: 307-313, 2009.
6. Chung CH, Ely K, McGavran L, et al: Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24: 4170-4176, 2006.
7. Zimmermann M, Zouhair A, Azria D and Ozsahin M: The epidermal growth factor recepter (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol 1: 11-16, 2006.
8. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuxi-mab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578, 2006.
9. Sharafinski ME, Ferris RL, Ferrone S and Grandis JR: Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck 32: 1412-1421, 2010.
10. Greene FL, WPage DL, Fleming ID, Fritz A, Balch CM, Haller DG and Morros M (eds): AJCC Cancer Staging Manual. 6th ed. Springer-Verlag, New York, 2002.
11. Mendelsohn J and Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21: 2787-2799, 2003.
12. Harney J, Short SC, Shah N, et al: Low dose hyperradiosensitivity in metastatic tumors. Int J Radiat Oncol Biol Phys 59: 1190-1195, 2004.
13. Lin PS and Wu A: Not all 2 Gray radiation prescriptions are equivalent: cytotoxic effect depends on delivery sequences of partial fractionated doses. Int J Radiat Oncol Biol Phys 63: 536-544, 2005.
14. Specenier P and Vermorken JB: Cetuximab in the treatment of squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther 11: 511-524, 2011.
15. Walsh L, Gillham C, Dunne M, et al: Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). Radiother Oncol 98: 38-41, 2011.
16. Pryor DI, Porceddu SV, Burmeister BH, et al: Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother Oncol 90: 172-176, 2009.
17. Bossi P, Liberatoscioli C, Bergamini C, et al: Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients. Ann Oncol 18: 601-602, 2007.
18. Kanakamedala MR, Packianathan S and Vijayakumar S: Lack of cetuximab induced skin toxicity in a previously irradiated field: case report and review of the literature. Radial Oncol 5: 38-41, 2010.